BeiGene Starts Trial of HPK1 Inhibitor, a Novel Immunocology Candidate

BeiGene of Beijing started a global Phase I trial of BGB-15025, a novel hematopoietic progenitor kinase 1 (HPK1) inhibitor, in patients with advanced solid tumor cancers. BGB-15025 is a small molecule oral inhibitor of HPK1, a kinase downstream of the T cell receptor signaling pathway that is thought to play a key role in T cell activation. BeiGene will test BGB-15025 as a monotherapy and in combination with its approved anti-PD-1 antibody, tislelizumab. More details.... Stock Symbols: (NSDQ: BGNE; HK: 06160) Share this with colleagues: // //